Dottorato in Medicina Molecolare

1. S. Mariani, M. Muraro, F. Pantaleoni, F. Fiore, B. Nuschak, S. Peola, M. Foglietta, A. Palumbo, M. Coscia, Castella B, B. Bruno, R. Bertieri, L. Boano, M. Boccadoro, M. Massaia. Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma.                      Leukemia 19: 664-670, 2005.
2. Fiore F, Castella B, Nushak B, Bertieri R, Mariani S, Bruno B, Pantaleoni F, Foglietta M, Boccadoro M, Massaia M. Enhanced ability of dendritic cells to stimulate innate and adaptive immunity upon short-term incubation with zoledronic acid.                                                                                     Blood 130: 921-927, 2007.
3. Coscia M, Pantaleoni F, Riganti C, Vitale C, Rigoni M, Peola S, Castella B,  Foglietta M, Griggio V, Drandi D, Ladetto M, Bosia A, Boccadoro M, Massaia M. IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells. Leukemia. 2011 May;25(5):828-37.
4. Castella B, Vitale C, Coscia M, Massaia M. Vγ9Vδ2 T cell-based immunotherapy in hematological malignancies: from bench to bedside.                                                                                           Cell Mol Life Sci. 2011 Jul;68(14):2419-32.
5. Castella B, Riganti C, Fiore F, Pantaleoni F, Canepari ME, Peola S, Foglietta M, Palumbo A, Bosia A, Coscia M, Boccadoro M, and Massaia M. Immune Modulation by Zoledronic Acid in Human Myeloma: an Advantageous Cross Talk between Vg9Vd2 T Cells, ab CD8+ T Cells, Regulatory T Cells, and Dendritic Cells.                                                                                                                            J Immunol. 2011 Aug;187(4):1578-90.
6. Coscia M, Vitale C, Peola S, Folgietta M, Rigoni M, Griggio V, Castella B, Angelini D. Chiaretti S, Riganti C, Guarini A, Drnadi D, Ladetto M, Bosia A, Foà R, Battistini L, Boccadoro M, Fournie JJ, Massaia M. Dysfunctional Vg9d2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells.                                            Blood 2012; 120(16):3271-9.
7. Riganti C, Castella B, Kopecka J, Campia I, Coscia M, Pescarmona G, Bosia A, Ghigo D, Massaia M. Zoledronic acid resotres doxorubicin chemosensitivity and immunogenic cell death in multidrug resistant human cancer cells.                                                                                                     Plos One 2013; 8(4):e60985.
8. Gelsomino G, Corsetto PA, Campia I, Montorfano G, Kopecka J, Castella B, Gazzano E, Ghigo D, Rizzo AM, Riganti C. Omega 3 fatty acids chemosensitize multidrug resistant colon cancer cells by down-regulating cholesterol synthesis and altering detergent resistant membranes composition.       Mol Cancer 2013; 12(1):137.

1. PANTALEONI F, MARIANI S, MURARO M, PEOLA S, NUSCHAK B, FOGLIETTA M, CASTELLA B., FIORE F, COSCIA M, BOCCADORO M, MASSAIA M (2004). Role of the mevalonate pathway in the immunomodulatory activity of zoledronic acid. In: Congresso nazionale SIES, 14-16 settembre 2004
2. MURARO M, MARIANI S, PANTALEONI F, FOLGIETTA M, FIORE F, NUSCHAK B, PEOLA S, CASTELLA B., COSCIA M, BOCCADORO M, MASSAIA M (2004). In vitro generation of antimyeloma activity by zoledronic acid: role of effector (CD45- CD27-) gamma delta T cells. In: VIII Congresso nazionale SIES, 14-16 settembre 2004
3. MASSAIA M, MARIANI S, PANTALEONI F, MURARO M, PEOLA S, HWANG SY, CASTELLA B., MATTA G, FOGLIETTA M, FIORE F, COSCIA M, BOCCADORO M (2005). Direct and indirect antitumor activity of zoledronic acid. In: Hematologica Reports. New drugs in hematology, 9-11 ottobre 2005, p. 77-80S.  
4. MARIANI S, PANTALEONI F, PEOLA S, HWANG SY, CASTELLA B., MATTA G, FOGLIETTA M, FIORE F, COSCIA M, BOCCADORO M, MASSAIA M (2005). Distribution of gamma/delta T cells in patients with hematologic malignancies. In: Hematologica Reports. Cervo, 6-8 ottobre 2005, vol. 2 
5. MASSAIA M, FIORE F, CASTELLA B., PANTALEONI F, MARIANI S, PEOLA S, HWANG SY, MATTA G (2006). Unconventional properties of zoledronic acid. In: Haematologica Reports. New Insights in hematology., 14-17 maggio 2006, vol. 2 
6. FOGLIETTA M, MARIANI S, CASTELLA B., COSCIA M, ZAPPIA S, BOCCADORO M, MASSAIA M (2006). Regulatory T Cells (Tregs) Are Highly Preserved in Multiple Myeloma Patients and Can Dominate Effector Functions. In: 48th ASH Annual Meeting. Orlando, Florida, 8-12 dicembre 2006 
7. FIORE F, CASTELLA B., MARIANI S, MASSAIA M (2006). dendritic cells incubation with zoledronate improves the ability to modulate innate and adaptive immune responses. In: IX Congresso della società italiana di Ematologia Sperimentale (SIES), 20-22 settembre  
8. FIORE F, CASTELLA B., MARIANI S, MASSAIA M (2006). Dendritic cells incubation with Zoledronate improves the ability to modulate innate and adaptive immune responses. In: 1st Joint Meeting of European National Societies of Immunology. Parigi, 6-9 settembre 2006 
9. FIORE F, CASTELLA B., ASSALTO C, ZAPPIA S, HWANG SY, VITALE C, BOCCADORO M, MASSAIA M (2007). The tryptophan metabolism in the immune dysregulation of multiple myeloma. In: Haematologica. BOLOGNA, 14-17 OTTOBRE 2007, vol. 92, ISBN/ISSN: 0390-6078
10. Coscia M, Cappello M, Griggio V, Linty F, Vitale C, Peola S, Castella B, Rigoni M, Drandi D, Ruggeri M, Omedè P, Ladetto M, Novelli F, Boccadoro M and Massaia M. Identification by Serological Proteome Analysis (SERPA) of tumor-associated antigens eliciting antibody responses in chronic lymphocytic leucemia (CLL). Blood 116: 917. 52th ASH Annual Meeting,December 4-7, 2010-Orlando,Florida.
11. Griggio V, Capello M, Linty F, Vitale C, Peola S, Cappello P, Castella B, Rigoni M, Sciancalepore P, Drandi D, Ruggeri M, Omedè P, Ladetto M, Novelli F, Boccadoro M, Massaia M, Coscia M. Identification by serological proteome analysis (Serpa) of tumor-associated antigens eliciting antibody-response in chronic lymphocytic leukemia. In: 43° Congress of the Italian Society of Hematology, Napoli, October 16-19, 2011 
12. Rigoni M, Coscia M, Riganti C, Campia I, Vitale C, Peola S, Castella B, Griggio V, Pantaleoni F, Sciancalepore P, Drandi D, Ladetto M, Bosia A, Boccadoro M, Massaia M. Targeting the mevalonate pathway and downstream signaling pathways as a strategy to circumvent multidrug- resistance in CLL Cells. In: 43° Congres of the Italian Society of Hematology Napoli, October 16-19, 2011 
13. Coscia M, Rigoni M, Riganti C, Campia I, Vitale C, Peola S, Griggio V, Castella B, Sciancalepore P, Drandi D, Ladetto M, Boccadoro M, Bosia A, Massaia M. Impact of the mevalonate pathway and HIF/PGP axis in modulating multidrug-resistance in unmutated CLL cells. EHA London, United Kingdom, June 9-12, 2011 
14. Coscia M, Griggio V, Capello M, Linty F, Vitale C, Peola S, Cappello P, Castella B, Rigoni M, Sciancalepore P, Drandi D, Ruggeri M, Omedè P, Ladetto M, Novelli F, Boccadoro M, Massaia M. Serological proteome analysis (Serpa) for the identification of tumor-associated antigens   eliciting antibody-responses in chronic lymphocytic leukemia. EHA London, United Kingdom, June 9-12, 2011 
15. Coscia M, Pantoleoni F, Riganti C, Vitale C, Rigoni M, Peola S, , Drandi D, Ladetto M, Ruggeri M, Griggio V, Castella B, Sciancalepore P,  Omedè P, Boccadoro M, Bosia A, Massaia M. IGHV unmutated CLL B cells are more porne to spontaneous apoptosis abd dpend from the anti-apoptotic   effect of the environmental signals. EHA London, United Kingdom, June 9-12, 2011

1. "The Tryptophan Metabolism In The Immune Dysregulation Of Multiple  Myeloma-Il Metabolismo Del Triptofano Nella Disregolazione Immunitaria Del Mieloma Multiplo". 41° Congresso della Società Italiana di Ematologia (SIE). Bologna 14-17 Ottobre 2007  
2. "Interazioni tra linfociti T regolatori (Tregs) e linfociti Vgamma9/Vdelta2 nel Mieloma Multiplo:un nuovo bersaglio di manipolazione immunologica". SIES (Società Italiana Ematologia Sperimentale) Discutiamone Insieme–Dalla biologia ai nuovi farmaci nel Mieloma Multiplo. Firenze, 11 Giugno 2009  
3. "Antitumor activity of aminobisphosphonates: from benches, to the bedside, and back". 4^th Cervo Preclinical Working Congress. Cervo, 1-3 Ottobre 2009  
4. "Recruitment of Vgamma9Vdelta2 T cells as antitumor effector cells and cellular adjuvants in Multiple Myeloma after short-term stimulation with dendritic cells copulsed with zoledronic acid and tumor-associated antigens". 4^th International gammadelta T Cell Conference. Kiel, Germany, 19-21 Maggio 2010  
5. “Activation of gd T cells by soluble IPP released by dendritic cells treated with zoledronic acid”. 5^th Cervo Preclinical Working Congress. Cervo, 6-8 Ottobre 2011
6. "Immunoparesys of bone marrow Vg9Vd2 T cells in human multiple myeloma" - 5th International gammadelta T cell conference - Freiburg, Germany, 31 May-2 June 2012
7. "Caratterizzazione di cellule immunosoppressorie nel microambiente tumorale del mieloma multiplo" IV Workshop Nazionale della Società Italiana di Ematologia Sperimentale                               Bologna, 14-15 Novembre 2013

- "A novel mechanism to inhibit HIV infection mediated by the chemokyne receptor CCR6" - Prof. Gazzino   Demo Alfredo

- "DNA vaccination from the lab to the clinic. The Southampton experience" - Dr. Ottensmeier Christian

- "Nanotecnology for cancer therapy: nanocarriers and biomechanism" - Dr. Leporatt

- "Adhesion molecules and growth factor receptors: a novel partnership that links receptor trafficking with cancer progression" - Dr. Cavallaro Ugo

- "In vivo activation of MAP-kinase and AKT signalling in breast carcinoma" - Dr. Ekkirala Ramesh

- "Human TH17: origin, differentiation, disease" - Dr. Depalma Raffaele